AIM ImmunoTech Inc. (AIM) |
|
0.84 0.01 (1.2%)
|
06-26 18:28 |
|
Open: |
0.85 |
Pre. Close: |
0.83 |
|
High:
|
0.865 |
Low:
|
0.8284 |
|
Volume:
|
80,682 |
Market Cap:
|
40(M) |
|
|
|
|
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.87 - 0.87 |
0.87 - 0.87 |
|
Low:
|
0.82 - 0.82 |
0.82 - 0.83 |
|
Close:
|
0.83 - 0.84 |
0.84 - 0.85 |
|
Technical analysis |
as of: 2022-06-24 4:37:54 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 1.09 One year: 1.22 |
| Support: |
Support1: 0.76 Support2: 0.63 |
| Resistance: |
Resistance1: 0.93 Resistance2: 1.04 |
| Pivot: |
0.84  |
| Moving Average: |
MA(5): 0.82  MA(20): 0.86
MA(100): 0.92 MA(250): 1.35 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 25 %D(3): 22.1 |
| RSI: |
RSI(14): 42.3 |
| 52-week: |
High: 2.2 Low: 0.55 |
| Average Vol(K): |
3-Month: 527 (K) 10-Days: 147 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AIM ] has closed above bottom band by 48.0%. Bollinger Bands are 40% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sun, 26 Jun 2022
Democratic candidates for U.S. Senate take aim at Ron Johnson at state convention - Madison.com
Sun, 26 Jun 2022
Duluth takes aim at vacant buildings, citing public safety risk - Duluth News Tribune
Sun, 26 Jun 2022
Opinion: A shared aim, shared accountability in driving to ‘functional zero’ on homelessness - OregonLive
Sun, 26 Jun 2022
Period-Tracker Apps Aim for Anonymity Following Roe v. Wade Decision - The Wall Street Journal
Sun, 26 Jun 2022
White Sox aim to break 4-game slide, play the Orioles - FOX Sports
Sun, 26 Jun 2022
Diamondbacks aim to break losing streak in matchup with the Tigers - The Associated Press - en Español
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
47 (M) |
|
% Held by Insiders
|
4.727e+007 (%) |
|
% Held by Institutions
|
1.3 (%) |
|
Shares Short
|
857 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.548e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-12 |
|
Return on Assets (ttm)
|
795.2 |
|
Return on Equity (ttm)
|
-16 |
|
Qtrly Rev. Growth
|
127000 |
|
Gross Profit (p.s.)
|
-0.02 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.31 |
|
Qtrly Earnings Growth
|
-0.4 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-11 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0 |
|
Price to Sales
|
275.18 |
|
Price to Cash Flow
|
-0.57 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
650280 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-06-10 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
